PROS1 and Alzheimer disease: Tanshinone IIA and ginsenoside Rb1 are AD medicines that upregulate the ratio of Bcl-2 (an antiapoptosis protein) to Bax (a proapoptotic protein) and downregulate caspase-3 (an effector of the main initiator in the apoptotic pathway) (Wang C. et al., 2018; He et al., 2020).